Bronchiectasis News and Research

RSS

Bronchiectasis is a condition in which the lung’s airways (bronchi) are dilated, causing an accumulation of mucus. This, in turn, makes the patient more vulnerable to infection, which can cause permanent damage. Most affected patients are middle-aged.

Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients

Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.

23 Feb 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

Aradigm commences patient dosage in Phase 2 trial of novel inhaled ciprofloxacin formulation

Aradigm Corporation today announced that the first patient was dosed in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in 40 adult patients with non-cystic fibrosis bronchiectasis.

16 Nov 2009

Third quarter 2009 financial results announced by Aradigm

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.

5 Nov 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

Data from Phase 1 and Phase 2a studies of inhaled liposomal ciprofloxacin to be presented at ERS Congress

Aradigm Corporation (OTCBB: ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 and Phase 2a studies at the ERS Annual Congress in Vienna, Austria, September 12-16, 2009.

14 Sep 2009

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Aradigm Corporation (OTCBB:ARDM) has announced that the European Medicines Agency (EMEA) granted Orphan Drug Designation to the Company’s inhaled liposomal ciprofloxacin drug product candidate for the treatment of lung infections associated with cystic fibrosis (“CF”).

6 Aug 2009

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.

12 Oct 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.

26 Jun 2008

Optical tool detects biomarkers in breath

Exhale on a cold winter day and you will see the water vapor coming out of your mouth.

20 Feb 2008

Health effects of passive somking studied in first-of-a-kind clinical study

Until bans on in-flight smoking took effect, beginning in 1988, flight attendants were regularly exposed to secondhand smoke.

1 Feb 2007

Exposure to arsenic in utero and early childhood tied to lung disease and cancer in adults

Children who are exposed to high levels of arsenic in their drinking water are seven to 12 times more likely to die of lung cancer and other lung diseases in young adulthood, a new study by University of California, Berkeley, and Chilean researchers suggests.

11 Apr 2006

Pharmaxis completes interim analysis on Bronchitol study

Sydney-based pharmaceutical company Pharmaxis Ltd has conducted an interim analysis on the Phase IIb clinical trial evaluating Bronchitol™ in patients with the respiratory condition bronchiectasis.

21 Jun 2004